Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 4:57 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,567 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Regimen Clear all
Terminated Phase 2 Interventional Results available

Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease

NCT03201445
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Filgotinib, Placebo, Standard of Care
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
21 Years to 65 Years · Male only
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
10
States / cities
San Diego, California • Lakewood Rch, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Nov 1, 2026, 4:57 AM EST
Completed Phase 2 Interventional Results available

A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State

NCT04451772
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Elsubrutinib, Placebo for Elsubrutinib, Upadacitinib, Placebo for Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
21
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Alamitos, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Nov 1, 2026, 4:57 AM EST
Completed Phase 2Phase 3 Interventional Results available

Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)

NCT00069641
View directory record Official record
Conditions
Mucopolysaccharidosis II
Interventions
iduronate-2-sulfatase enzyme replacement therapy, Placebo
Biological
Lead sponsor
Shire
Industry
Eligibility
5 Years to 25 Years · Male only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
4
States / cities
Oakland, California • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Nov 1, 2026, 4:57 AM EST
Completed Phase 3 Interventional Results available

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

NCT02000622
View directory record Official record
Conditions
Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
Interventions
Olaparib, Physician's choice chemotherapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
42
States / cities
San Diego, California • Santa Rosa, California • Whittier, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 1, 2026, 4:57 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual B...

NCT02511054
View directory record Official record
Conditions
Malaria
Interventions
Chloroquine (CQ), Pyrimethamine (PYR), Sanaria PfSPZ Challenge (NF54)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 1, 2026, 4:57 AM EST
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Effect of Post-operative Ibuprofen After Surgery for Chronic Rhinosinusitis

NCT03055507
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis)
Interventions
Ibuprofen 400 mg, Acetaminophen 650 mg, OxyCODONE 5 Mg Oral Tablet
Drug
Lead sponsor
University of Washington
Other
Eligibility
Not listed
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Nov 1, 2026, 4:57 AM EST
Completed Phase 2 Interventional

Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma

NCT00734292
View directory record Official record
Conditions
Mild to Moderate Asthma
Interventions
fluticasone propionate, formoterol fumarate, fluticasone propionate, formoterol fumarate
Drug · Other
Lead sponsor
SkyePharma AG
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
8
States / cities
Anaheim, California • Mission Viejo, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Nov 1, 2026, 4:57 AM EST
Recruiting Not applicable Interventional

Opioid-Free Pain Treatment in Trauma Patients

NCT06078371
View directory record Official record
Conditions
Femoral Neck Fractures, Intertrochanteric Fractures, Femoral Shaft Fracture, Distal Femur Fracture, Patella Fracture, Tibial Shaft Fracture with or Without Associated Fibula Fracture, Ankle Fracture (bimalleolar Equivalent, Bimalleolar, or Trimalleolar), Tibial Pilon Fracture, Talar Head, Neck, Body, or Process Fractures, Calcaneus Fractures, Lisfranc Injuries, Isolated or Multiple Metatarsal Fractures, Phalanx Fractures of the Foot, Single or Multiple, Clavicle Fractures, Proximal Humerus Fractures, Humeral Shaft Fractures, Distal Humerus Fractures (intra or Extra-articular), Olecranon Fractures, Radial Head or Neck Fractures, Elbow Fractures Involving a Combination of Fractures of the Radius and Uln, Forearm Fractures (both Bone Forearm Fractures, Isolated Ulnar Shaft, Isolated Radial Shaft), Distal Radius Fractures
Interventions
Opioid-free pain treatment
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Nov 1, 2026, 4:57 AM EST
Completed Not applicable Interventional

Preventing Falls Through Enhanced Pharmaceutical Care

NCT00618800
View directory record Official record
Conditions
Falls
Interventions
Pharmaceutical Care, Written Materials
Behavioral · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Nov 1, 2026, 4:57 AM EST
Recruiting Not applicable Interventional

Continuous Glucose Monitors (CGMs) for All: Studying the Impact of Expanding CGM Access

NCT06658067
View directory record Official record
Conditions
Diabetes, Type 2 Diabetes, Type 2 Diabetes Mellitus - Poor Control
Interventions
Continuous Glucose Monitor (CGM)
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Nov 1, 2026, 4:57 AM EST
Not listed Phase 2 Interventional

Safety and Efficacy Study of Autologous Engineered Skin Substitute to Treat Partial- and Full-Thickness Burn Wounds

NCT01655407
View directory record Official record
Conditions
Thermal Injury, Deep Partial-Thickness Burn, Full-Thickness Burn
Interventions
Autologous Engineered Skin Substitute, Split-Thickness Autograft (AG)
Drug
Lead sponsor
Amarantus BioScience Holdings, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Pheonix, Arizona • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Nov 1, 2026, 4:57 AM EST
Completed Phase 2 Interventional Results available

SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx

NCT03220854
View directory record Official record
Conditions
Solid Tumor
Interventions
Stereotactic radiotherapy, Biological: humanized anti-PD-1 monoclonal antibody, Biological: humanized anti-PD-L1 monoclonal antibody
Radiation · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Nov 1, 2026, 4:57 AM EST
Completed Phase 3 Interventional Results available

A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).

NCT00863746
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Fayetteville, Arkansas • Stanford, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Nov 1, 2026, 4:57 AM EST
Recruiting Phase 4 Interventional Accepts healthy volunteers

Optimizing Pain Control in Transurethral Resection of the Prostate

NCT04102566
View directory record Official record
Conditions
Pain, BPH With Urinary Obstruction, BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms
Interventions
Ibuprofen 600 mg, Education
Drug · Behavioral
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Nov 1, 2026, 4:57 AM EST
Completed Phase 2 Interventional Results available

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

NCT03373383
View directory record Official record
Conditions
Drug-resistant Epilepsy, Focal-Onset Seizures
Interventions
Padsevonil, Placebo
Drug · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
27
States / cities
Chandler, Arizona • Little Rock, Arkansas • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Nov 1, 2026, 4:57 AM EST
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)

NCT04618744
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis
Interventions
ORMD-0801 (Insulin) capsule 8 mg BD, Placebo
Drug · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Nov 1, 2026, 4:57 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Efficacy, Cycle Control, and Safety of a NES-E2 Contraceptive Vaginal Ring

NCT03432416
View directory record Official record
Conditions
Healthy Women, Female Contraception
Interventions
NES-E2 CVR
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
11
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Nov 1, 2026, 4:57 AM EST
Completed Not applicable Interventional

Parent Mentors to Improve Adherence to Type I Diabetes Care Regimen in Adolescents

NCT03199716
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Parent mentors
Other
Lead sponsor
University of California, Davis
Other
Eligibility
10 Years to 15 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Nov 1, 2026, 4:57 AM EST
Completed Not applicable Interventional

Bacterial Decolonization Within Dyads

NCT06541145
View directory record Official record
Conditions
Bacterial Colonization
Interventions
Mupirocin, Chlorhexidine baths
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Nov 1, 2026, 4:57 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD

NCT02498301
View directory record Official record
Conditions
Travelers' Diarrhea, Functional Bowel Disorders, Reactive Arthritis
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
5
States / cities
San Diego, California • Honolulu, Hawaii • Marine Corps Base Camp Lejeune, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Nov 1, 2026, 4:57 AM EST
Not yet recruiting Phase 4 Interventional

The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)

NCT07276802
View directory record Official record
Conditions
Post Cataract Surgery
Interventions
Triamcinolone (Optional), control group
Drug
Lead sponsor
Research Insight LLC
Industry
Eligibility
22 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Nov 1, 2026, 4:57 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers

Safety and Efficacy of a Contraceptive Vaginal Ring Delivering Nestorone® and Ethinyl Estradiol

NCT00263341
View directory record Official record
Conditions
Contraception
Interventions
NES/EE CVR
Combination Product
Lead sponsor
Population Council
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
1,135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Nov 1, 2026, 4:57 AM EST
Recruiting Early Phase 1 Interventional

Early Use of Long-acting Tacrolimus in Lung Transplant Recipients

NCT04469842
View directory record Official record
Conditions
Lung Transplant; Complications
Interventions
Tacrolimus Extended Release Oral Tablet [Envarsus], Tacrolimus, Mycophenolate Mofetil Hydrochloride, Prednisone, Azathioprine
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Nov 1, 2026, 4:57 AM EST
Completed Phase 2 Interventional

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

NCT01684761
View directory record Official record
Conditions
Autoimmune Diseases of the Nervous System, Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Disease Progression, Brain Atrophy
Interventions
Tcelna, Placebo
Biological
Lead sponsor
Opexa Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Nov 1, 2026, 4:57 AM EST